A Phase 1, Open-Label, Single-Dose Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Erdafitinib (Primary)
- Indications Breast cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 06 Dec 2018 Planned initiation date changed from 12 Nov 2018 to 6 Dec 2018.
- 09 Nov 2018 Planned initiation date changed from 31 Oct 2018 to 12 Nov 2018.
- 05 Sep 2018 Planned initiation date changed from 9 Jul 2018 to 31 Oct 2018.